Catalyst Pharmaceuticals Inc (CPRX)
Interest coverage
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | — | 86,812 | 101,838 | 52,385 | 41,303 |
| Interest expense | US$ in thousands | — | — | 4,120 | 474 | 1,472 |
| Interest coverage | — | — | 24.72 | 110.52 | 28.06 |
December 31, 2024 calculation
Interest coverage = EBIT ÷ Interest expense
= $—K ÷ $—K
= —
Based on the provided data, Catalyst Pharmaceuticals Inc's interest coverage ratio has shown significant improvement over the years.
As of December 31, 2020, the interest coverage ratio was 28.06, indicating that the company earned 28.06 times more operating income than it needed to cover its interest expenses. This demonstrates a strong ability to meet its interest obligations.
By December 31, 2021, the interest coverage ratio improved further to 110.52, showcasing a substantial increase in the company's ability to cover its interest expenses comfortably.
However, there was a slight decline in the interest coverage ratio by December 31, 2022, to 24.72. Although this ratio is still considered healthy, it is lower compared to the previous year.
The data for December 31, 2023, and December 31, 2024, is not provided (indicated as "—"), making it challenging to assess the trend beyond 2022.
Overall, the trend in Catalyst Pharmaceuticals Inc's interest coverage ratio is positive, with significant improvements seen up to 2021, although there was a slight dip in 2022. Investors and stakeholders should continue monitoring the company's future financial performance to ensure its ability to meet interest obligations remains strong.
Peer comparison
Dec 31, 2024